Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

919
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
919
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.0K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

1.6K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.6K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

845
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
845
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Dietary Protein Quantity, Source, and Type on Plasma Lipids and Lipoproteins and Their Roles in Dyslipidemia Management in Humans.

Nutrients·2026
Same author

Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trials.

American journal of preventive cardiology·2026
Same author

From the Editors: Lipoprotein(a), inflammation, and residual ASCVD risk plus further evidence of greater benefits of LDL-C reduction in primary prevention.

Journal of clinical lipidology·2026
Same author

JCL Roundtable: Lipid metabolism, brain health, and dementia prevention.

Journal of clinical lipidology·2026
Same author

Comparative efficacy and safety of olezarsen vs plozasiran for familial chylomicronemia syndrome: A matching-adjusted indirect comparison.

Journal of clinical lipidology·2026
Same author

How does prior infection and vaccination relate to the risk of incident SARS-CoV-2 infection/reinfection? A prospective cohort study among nine clinical sites in the USA, February 2021 to January 2023.

BMJ open·2026

Related Experiment Video

Updated: Mar 25, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Statins and Diabetes.

Kevin C Maki1, Mary R Dicklin1, Seth J Baum2

  • 1Metabolic Sciences, Midwest Center for Metabolic & Cardiovascular Research, 489 Taft Avenue, Suite 202, Glen Ellyn, IL 60137, USA.

Endocrinology and Metabolism Clinics of North America
|February 20, 2016
PubMed
Summary

Statins, a first-line treatment for high cholesterol, may increase type 2 diabetes risk. However, the heart benefits of statins outweigh this risk, with guidelines recommending continued use and diabetes monitoring.

Keywords:
Cardiovascular diseaseCoronary heart diseaseDiabetes mellitusDyslipidemiaGlucoseGlycemiaHigh intensity statinsStatins

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.7K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Related Experiment Videos

Last Updated: Mar 25, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.7K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Statins are primary medications for managing dyslipidemia.
  • Clinical trials indicate a potential link between statin use and new-onset type 2 diabetes mellitus.
  • The National Lipid Association (NLA) established a task force to evaluate statin safety concerning diabetes.

Purpose of the Study:

  • To review the evidence on statin use and incident diabetes.
  • To summarize the NLA Statin Diabetes Safety Task Force conclusions.
  • To provide clinical recommendations for managing patients on statin therapy regarding diabetes risk.

Main Methods:

  • Review of clinical trial data and existing literature on statin therapy and diabetes.
  • Analysis of the NLA Statin Diabetes Safety Task Force's findings.
  • Incorporation of recent study results and established diabetes care guidelines.

Main Results:

  • The cardiovascular benefits of statin therapy are generally considered to outweigh the risk of developing diabetes.
  • The NLA panel recommends adhering to American Diabetes Association standards for diabetes screening and diagnosis.
  • Emphasis is placed on the critical role of lifestyle modifications in managing dyslipidemia and diabetes risk.

Conclusions:

  • Statin therapy remains a crucial intervention for cardiovascular risk reduction.
  • Patients on statins should be monitored for diabetes, following current screening protocols.
  • Lifestyle interventions are paramount for both cardiovascular health and diabetes prevention/management.